{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:17:21Z","timestamp":1792095441625,"version":"4.4.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s11864-020-0704-8","type":"journal-article","created":{"date-parts":[[2020,2,5]],"date-time":"2020-02-05T05:03:51Z","timestamp":1580879031000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Nausea and Vomiting in Advanced Cancer"],"prefix":"10.1007","volume":"21","author":[{"given":"Rudolph M.","family":"Navari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,5]]},"reference":[{"key":"704_CR1","unstructured":"NCCN Clinical practice guidelines in oncology. Palliative care version 2.2019; 2019. Accessed 7\/15\/2019. Recommendations for treatment of nausea and vomiting in advanced cancer patients."},{"key":"704_CR2","unstructured":"Navari RM. Managing nausea and vomiting in patients with cancer: what works. Oncology (Williston Park). 2018;32:121\u20135 31, 36. Clinical approach to treatment of nausea in advanced cancer patients."},{"key":"704_CR3","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/j.jpainsymman.2009.08.010","volume":"39","author":"MP Davis","year":"2010","unstructured":"Davis MP, Hallerberg G, Palliative Medicine Study Group of the Multinational Association of Supportive Care in C. A systematic review of the treatment of nausea and\/or vomiting in cancer unrelated to chemotherapy or radiation. J Pain Symptom Manag. 2010;39:756\u201367.","journal-title":"J Pain Symptom Manag"},{"key":"704_CR4","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1002\/cncr.24017","volume":"115","author":"MO Delgado-Guay","year":"2009","unstructured":"Delgado-Guay MO, Parsons HA, Li Z, Palmer LJ, Bruera E. Symptom distress, interventions, and outcomes of intensive care unit cancer patients referred to a palliative care consult team. Cancer. 2009;115:437\u201345.","journal-title":"Cancer"},{"key":"704_CR5","first-page":"8","volume":"11","author":"M Gupta","year":"2013","unstructured":"Gupta M, Davis M, LeGrand S, Walsh D, Lagman R. Nausea and vomiting in advanced cancer: the Cleveland Clinic protocol. J Support Oncol. 2013;11:8\u201313.","journal-title":"J Support Oncol"},{"issue":"1","key":"704_CR6","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1089\/jpm.2017.0159","volume":"21","author":"Madeline Digges","year":"2018","unstructured":"Digges M, Hussein A, Wilcock A, Crawford GB, Boland JW, Agar MR, et al. Pharmacovigilance in hospice\/palliative care: net effect of haloperidol for nausea or vomiting. J Palliat Med. 2018;21:37\u201343.","journal-title":"Journal of Palliative Medicine"},{"issue":"4","key":"704_CR7","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.jpainsymman.2004.01.009","volume":"28","author":"Eduardo Bruera","year":"2004","unstructured":"Bruera E, Moyano JR, Sala R, Rico MA, Bosnjak S, Bertolino M, et al. Dexamethasone in addition to metoclopramide for chronic nausea in patients with advanced cancer: a randomized controlled trial. J Pain Symptom Manag. 2004;28:381\u20138.","journal-title":"Journal of Pain and Symptom Management"},{"key":"704_CR8","doi-asserted-by":"publisher","first-page":"e029942","DOI":"10.1136\/bmjopen-2019-029942","volume":"9","author":"JR Hardy","year":"2019","unstructured":"Hardy JR, Skerman H, Phillip J, et al. Methotrimeprazine versus haloperidol in palliative care patients with cancer-related nausea; a randomized double-blind controlled trial. BMJ Open. 2019;9:e029942.","journal-title":"BMJ Open"},{"key":"704_CR9","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1186\/s12885-018-4404-8","volume":"18","author":"J Hardy","year":"2018","unstructured":"Hardy J, Skerman H, Glare P, et al. A randomized open-label study of guideline-driven antiemetic therapy versus single agent antiemetic therapy in patients with advanced cancer and nausea not related to anticancer treatment. BMC Cancer. 2018;18:510.","journal-title":"BMC Cancer"},{"key":"704_CR10","doi-asserted-by":"publisher","first-page":"e6","DOI":"10.1016\/j.jpainsymman.2019.05.004","volume":"58","author":"H Matsuoka","year":"2019","unstructured":"Matsuoka H, Agar M, Vandersman Z, et al. Harms from haloperidol for symptom management in palliative care - a post hoc pooled analysis of three randomized controlled studies and two consecutive cohort studies. J Pain Symptom Manage. 2019;58:e6\u20138.","journal-title":"J Pain Symptom Manage"},{"key":"704_CR11","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1056\/NEJMra1515442","volume":"374","author":"RM Navari","year":"2016","unstructured":"Navari RM, Aapro M. Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting. N Engl J Med. 2016;374:1356\u201367.","journal-title":"N Engl J Med"},{"key":"704_CR12","doi-asserted-by":"publisher","first-page":"6459","DOI":"10.2147\/OTT.S158570","volume":"11","author":"RM Navari","year":"2018","unstructured":"Navari RM, Schwartzberg L. Evolving role of neurokinin 1 receptor antagonists for chemotherapy-induced nausea and vomiting. OncoTargets Ther. 2018;11:6459\u201378.","journal-title":"OncoTargets Ther"},{"key":"704_CR13","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.cmonc.2011.11.001","volume":"9","author":"RM Navari","year":"2012","unstructured":"Navari RM. Treatment of chemotherapy-induced nausea. Commun Oncol. 2012;9:20\u20136.","journal-title":"Commun Oncol"},{"key":"704_CR14","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1634\/theoncologist.2014-0438","volume":"20","author":"TL Ng","year":"2015","unstructured":"Ng TL, Hutton B, Clemons M. Chemotherapy-induced nausea and vomiting. Time for more emphasis on nausea? Oncologist. 2015;20:576\u201383.","journal-title":"Oncologist"},{"key":"704_CR15","doi-asserted-by":"publisher","first-page":"243","DOI":"10.2147\/CIA.S13109","volume":"6","author":"P Glare","year":"2011","unstructured":"Glare P, Miller J, Nikolova T, et al. Treating nausea and vomiting in palliative care: a review. Clin Interv Aging. 2011;6:243\u201359.","journal-title":"Clin Interv Aging"},{"key":"704_CR16","first-page":"103","volume":"1","author":"HS Smith","year":"2012","unstructured":"Smith HS, Smith JM, Smith AR. An overview of nausea\/vomiting in palliative medicine. Ann Palliat Med. 2012;1:103\u201314.","journal-title":"Ann Palliat Med"},{"key":"704_CR17","unstructured":"NCCN Practice guidelines in oncology. Antiemesis version 1.2019 - February 28, 2019. Recommendatiosn for treatment of CINV."},{"key":"704_CR18","doi-asserted-by":"crossref","unstructured":"Walsh D, Davis D, Ripoamonti C, et al. 2016 Updated MASCC\/ESMO consensus recommendations management of nauea and vomiting in advanced cancer patients. Spport Care Cancer. 2017:333\u201340. Recommendations for treatment of nausea and vomiting in advanced cancer patients.","DOI":"10.1007\/s00520-016-3371-3"},{"key":"704_CR19","doi-asserted-by":"publisher","first-page":"3240","DOI":"10.1200\/JCO.2017.74.4789","volume":"35","author":"PJ Hesketh","year":"2017","unstructured":"Hesketh PJ, Kris MG, Basch E, et al. ASCO antiemetic guidelines. J Clin Oncol. 2017;35:3240\u201361.","journal-title":"J Clin Oncol"},{"key":"704_CR20","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1007\/s00520-009-0739-7","volume":"18","author":"RM Navari","year":"2010","unstructured":"Navari RM, Brenner MC. Treatment of cancer related anorexia with megestrol acetate and olanzapine. Support Care Cancer. 2010;18:951\u20136.","journal-title":"Support Care Cancer"},{"issue":"2","key":"704_CR21","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1056\/NEJMoa1515725","volume":"375","author":"Rudolph M. Navari","year":"2016","unstructured":"Navari RM, Qin R, Ruddy KJ, Liu H, Powell SF, Bajaj M, et al. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. N Engl J Med. 2016;375:134\u201342.","journal-title":"New England Journal of Medicine"},{"key":"704_CR22","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1007\/s00520-012-1710-6","volume":"21","author":"RM Navari","year":"2013","unstructured":"Navari RM, Nagy CK, Gray SE. The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer. 2013;21:1655\u201363.","journal-title":"Support Care Cancer"},{"key":"704_CR23","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1177\/1049909112441241","volume":"30","author":"E Prommer","year":"2012","unstructured":"Prommer E. Olanzapine: palliative medicine update. Am J Hosp Palliat Med. 2012;30:75\u201382.","journal-title":"Am J Hosp Palliat Med"},{"key":"704_CR24","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1089\/109662103764978506","volume":"6","author":"WC Jackson","year":"2003","unstructured":"Jackson WC, Tavernier L. Olanzapine for intractable nausea in palliative care patients. J Palliat Med. 2003;6:251\u20135.","journal-title":"J Palliat Med"},{"key":"704_CR25","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.jpainsymman.2011.10.023","volume":"44","author":"K Kaneishi","year":"2012","unstructured":"Kaneishi K, Kawabata M, Morita T. Olanzapine for the relief of nausea in patients with advanced cancer and incomplete bowel obstruction. J Pain Symptom Manag. 2012;44:604\u20137.","journal-title":"J Pain Symptom Manag"},{"key":"704_CR26","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1177\/1049909110369532","volume":"27","author":"N Licup","year":"2010","unstructured":"Licup N. Olanzapine for nausea and vomiting. Am J Hosp Palliat Care. 2010;27:432\u20134.","journal-title":"Am J Hosp Palliat Care"},{"issue":"5","key":"704_CR27","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/S0885-3924(03)00078-2","volume":"25","author":"Steven D Passik","year":"2003","unstructured":"Passik SD, Kirsh KL, Theobald DE, Dickerson P, Trowbridge R, Gray D, et al. A retrospective chart review of the use of olanzapine for the prevention of delayed emesis in cancer patients. J Pain Symptom Manag. 2003;25:485\u20138.","journal-title":"Journal of Pain and Symptom Management"},{"key":"704_CR28","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1002\/(SICI)1099-1611(200001\/02)9:1<84::AID-PON440>3.0.CO;2-T","volume":"9","author":"WF Pirl","year":"2000","unstructured":"Pirl WF, Roth AJ. Remission of chemotherapy-induced emesis with concurrent olanzapine treatment: a case report. Psychooncology. 2000;9:84\u20137.","journal-title":"Psychooncology"},{"key":"704_CR29","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/S0885-3924(03)00143-X","volume":"25","author":"M Srivastava","year":"2003","unstructured":"Srivastava M, Brito-Dellan N, Davis MP, Leach M, Lagman R. Olanzapine as an antiemetic in refractory nausea and vomiting in advanced cancer. J Pain Symptom Manag. 2003;25:578\u201382.","journal-title":"J Pain Symptom Manag"},{"issue":"6","key":"704_CR30","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S0885-3924(02)00391-3","volume":"23","author":"Steven D. Passik","year":"2002","unstructured":"Passik SD, Lundberg J, Kirsh KL, Theobald D, Donaghy K, Holtsclaw E, et al. A pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced cancer and pain. J Pain Symptom Manag. 2002;23:526\u201332.","journal-title":"Journal of Pain and Symptom Management"},{"key":"704_CR31","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1097\/SPC.0000000000000206","volume":"10","author":"SM Bosnjak","year":"2016","unstructured":"Bosnjak SM, Dimitrijevic J, Djordjevic F. Cancer and chemotherapy-induced nausea and vomiting: a focus on olanzapine. Curr Opin Support Palliat Care. 2016;10:180\u20138.","journal-title":"Curr Opin Support Palliat Care"},{"key":"704_CR32","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.ejphar.2013.08.048","volume":"722","author":"RM Navari","year":"2014","unstructured":"Navari RM. Olanzapine for the prevention and treatment of chronic nausea and chemotherapy-induced nausea and vomiting. Eur J Pharmacol. 2014;722:180\u20136.","journal-title":"Eur J Pharmacol"},{"key":"704_CR33","doi-asserted-by":"crossref","unstructured":"Navari RM, Pywell CM, Le-Rademacher JG, et al. Olanzapine for the treatment of advanced cancer-related chronic nausea and\/or vomiting. ASCP Palliative Care Symposium San Francisco, October, 2019. Randomized clinicaltrial demonstrating the effectiveness of olanzapine in chronic nausea in advanced cancer patients.","DOI":"10.1001\/jamaoncol.2020.1052"},{"key":"704_CR34","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s00520-016-3324-x","volume":"25","author":"A Molassiotis","year":"2017","unstructured":"Molassiotis A, Aapro M, Herrstedt, et al. MASCC\/ESMO antiemetics guidelines: introduction to the 2016 guideline update. Support Care Cancer. 2017;25:267\u20139.","journal-title":"Support Care Cancer"},{"key":"704_CR35","first-page":"13","volume":"17","author":"RM Navari","year":"2016","unstructured":"Navari RM. Should behavioral therapy be used as the primary treatment to control anticipatory vomiting? HemeOnc Today. 2016;17:13.","journal-title":"HemeOnc Today"},{"key":"704_CR36","first-page":"102","volume":"2","author":"RM Navari","year":"2017","unstructured":"Navari RM. Cancer patients at high risk for chemotherapy-induced nausea and vomiting - prediction assessment\/tools. Expert Rev Quality Cancer Care. 2017;2:102\u20138.","journal-title":"Expert Rev Quality Cancer Care"},{"key":"704_CR37","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.ejphar.2013.09.071","volume":"722","author":"C Kamen","year":"2014","unstructured":"Kamen C, Mohamedtaki A, Tejani KC, et al. Anticipatory nausea and vomiting due to chemotherapy. Eur J Pharmacol. 2014;722:172\u20139.","journal-title":"Eur J Pharmacol"},{"key":"704_CR38","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1007\/s00520-017-3685-9","volume":"25","author":"K Dennis","year":"2017","unstructured":"Dennis K, Rehana J, McGrath C, et al. A systematic review of methodologies, endpoints, and outcome measures in randomized trials of radiation therapy-induced nausea and vomiting. Support Care Cancer. 2017;25:2019\u201333.","journal-title":"Support Care Cancer"},{"key":"704_CR39","first-page":"50","volume":"5","author":"N Chiu","year":"2016","unstructured":"Chiu N, Chiu L, Popovic M, et al. Latest advances in the management of radiation-induced pain flare, nausea and vomiting. Ann Palliat Med. 2016;5:50\u20137.","journal-title":"Ann Palliat Med"},{"key":"704_CR40","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s00520-016-3423-8","volume":"25","author":"L Thamlikitkul","year":"2017","unstructured":"Thamlikitkul L, Srimuninnimit V, Akewanlop C, et al. Efficacy of ginger for the prophylaxis of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adriamycin-cyclophosphamide regimen: a randomized, double-blind placebo-controlled crossover study. Support Care Cancer. 2017;25:459\u201364.","journal-title":"Support Care Cancer"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-020-0704-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11864-020-0704-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-020-0704-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,4]],"date-time":"2021-02-04T00:20:20Z","timestamp":1612398020000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11864-020-0704-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["704"],"URL":"https:\/\/doi.org\/10.1007\/s11864-020-0704-8","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"5 February 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Rudolph M. Navari declares that he has no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"14"}}